Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Hip Fracture Patients:...

    Hip Fracture Patients: Alendronate reduces CVD risk, says Study

    Written by Vinay Singh singh Published On 2018-05-21T20:00:52+05:30  |  Updated On 21 May 2018 8:00 PM IST
    Hip Fracture Patients: Alendronate reduces CVD risk, says Study

    The risk of cardiovascular events in patients with hip fracture treated with Alendronate gets significantly reduced, according to a recent study. Hip fracture generally results in an increased risk of cardiovascular events such as myocardial infarction (MI), stroke, and cardiovascular mortality. Alendronate reduced cardiovascular mortality by 67% and myocardial infarction risk by 45%.


    Cardiovascular events refer to any incidents that may cause damage to the heart muscle. The heart constantly pumps blood filled with oxygen and nutrients through the arteries, into the heart muscle (myocardium). Any interruption of blood flow will lead to an injury or infarction.


    Chor-Wing Sing and his associates conducted a study to investigate the risk of CVE with and without the use of alendronate in patients with hip fracture.


    In total, 34,991 patients with average age of 82 years were included in the study. 8.2% received a drug to treat osteoporosis in the first year following discharge, and 13.2% received treatment by the end of the study.


    4594 patients exposed to osteoporosis treatment and 123,568 patients not exposed to the treatment. Median follow-up was slightly shorter, at 1349 days, in those who had not been treated, compared with 1371 days in those who had been treated. Two-thirds of the treated group received alendronate (67%), and almost all were treated weekly rather than daily.


    The study found that Alendronate was associated with a significantly lower risk of 1‐year cardiovascular mortality and incident myocardial infarction whereas there was a marginally significant reduction in risk of stroke at 5 years and 10 years. The strength of the association declined over time but remained significant.


    Similarly, the risk of MI was 45% lower among patients treated with alendronate vs control. In contrast, there was no difference in physical functioning or survival between those treated or not treated with alendronate.


    The researchers suggested that bisphosphonates might lower cardiovascular event risk by indirectly targeting the mevalonate pathway — the same pathway statins target — suggesting bisphosphonates may have a cholesterol-lowering effect.


    The study concluded that there is a clinical need to be aware of this increased risk of cardiovascular events among patients who sustain a hip fracture and intervene to reduce these life-threatening outcomes and the emphasized the importance of initiating alendronate treatment after hip fracture.


    The study was published in Journal of Bone and Mineral Research.


    For more reference log on to: https://doi.org/10.1002/jbmr.3448


    biphosphonatesblood flowcardiovascularcholesterolChor Wing SingCVEHeartHip fractureinjuryJournal of Bone and Mineral Researchmevalonatemortalitymyocardial infarctionmyocardiumosteoporosis
    Source : With inputs from the Journal of Bone and Mineral Research

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok